Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

Overview

This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate

Full Title of Study: “The Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2014

Detailed Description

Visit 1 – Initial Application: – A patient candidate identified by the PI who meets all of the inclusion criteria and none of the exclusion criteria will be consented for the study. – The medical history will be collected from the subject. – The subject will receive routine hemodialysis – Directly after the completion of hemodialysis, the following study drug application steps will occur: 1. Site 1 Initial Compression: Apply fixed amount of Tranexamic acid and bacitracin 5% or 25% to gauze and compress for 3 minutes to needle site 1. 2. Site 2 Initial Compression: Apply fixed amount of Tranexamic acid and bacitracin 5% or 25% to gauze and compress for 3 minutes to needle site 2. 3. Second Compression per site: If bleeding has not stopped, repeat application with new gauze and same amount of ointment to each respective site and compress for 5 minutes more at each site. 4. Third Compression per site: If after the second application and compression the bleeding persists repeat both application and compression for another 5 minutes (total time would be 13 minutes at this step). 5. Test Failure: If after the third application to each needle site there is still bleeding, the testing would be considered a failure and routine procedures should be utilized to stop the bleeding. – Any adverse events will be collected. Visit 2 – Follow-Up: • The 1 week follow up visit will be performed to review study drug application site and to collect any adverse events reported by subject The clotting time will be compared to the clotting time at a different dialysis session in which no treatment will be used

Interventions

  • Drug: Topical Tranexamic Acid 5% with bacitracin
    • Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
  • Other: Topical Tranexamic Acid 25% with bacitracin
    • Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

Arms, Groups and Cohorts

  • Experimental: Clotting time Using Tranexamic Acid 5%
    • Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
  • Experimental: Clotting Time Using Tranexamic Acid 25%
    • Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis

Clinical Trial Outcome Measures

Primary Measures

  • Clotting TIme
    • Time Frame: 13 minutes
    • After completing dialysis, the clotting time of the arteriovenous fistula of each participant was measured, using either Tranexamic Acid 5% or Tranexamic Acid 25% and compared to the regular clotting time of the AV Fistula without using the Tranexamic Acid

Secondary Measures

  • Local Infection
    • Time Frame: 2 months
    • After using Tranexamic Acid and Bacitracin, local infection rate measured at the end of study

Participating in This Clinical Trial

Inclusion Criteria

  • Dialysis patients with fistulas (native arterio-venous) Exclusion Criteria:

  • Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin. – Active infection. – Stenosis of fistula.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • California Institute of Renal Research
  • Collaborator
    • Imprimis Pharmaceuticals, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mark Boiskin, MD – California Institute of Renal Research
  • Overall Official(s)
    • Mark Boiskin, MD, Principal Investigator, California Institute of Renal Research

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.